Prenatal Covid Vaccination Proves Effective; How successful is Jynneos in preventing monkeypox?

Read more about the biggest pharmaceutical developments and price stories over the past week in KHN’s Prescription Drug Watch round-up.

CIDRAP: COVID vaccines in pregnancy are associated with a reduced risk of NICU stay and stillbirth

COVID-19 vaccination during pregnancy was associated with a reduced risk of neonatal intensive care unit (NICU) admission, stillbirth, and maternal SARS-CoV-2 infection, and no additional risk of preterm birth, small for gestational age ( SGA), low Apgar score, cesarean section, postpartum hemorrhage, or chorioamnionitis, finds a systematic review and meta-analysis published yesterday in JAMA Pediatrics. (Beusekom, October 4th)

CIDRAP: Study raises further questions about the effectiveness of monkeypox vaccines

A new study published in JAMA documents 90 cases of monkeypox after one or two doses of the Jynneos vaccine — including 2 infections 3 weeks or more after two doses — among more than 7,000 vaccine recipients. (Soucheray, 3.10.)

FiercePharma: FDA warns that AZ’s Evusheld is less effective against new subvariants

On Monday, amid reports that the combination of antibodies against Omicron’s newest subvariant, BA.4.6, is ineffective, the FDA updated its data sheet (PDF) for Evusheld, stating that there is a risk of COVID-19 infection for variants can increase, which the product does not neutralize. (Dunleavy, 4.10.)

Miami Herald: Recall: Blood pressure medication bottles containing medication for heart patients

Bottles of drugs used to lower blood pressure contained drugs used to prevent strokes and blood clots in people with heart disease, prompting a recall of one batch at a time. (Neal, 2.10.)

Reuters: AstraZeneca pays 660% premium for gene therapy company LogicBio

LogicBio Therapeutics’ shares soared Monday after Britain’s AstraZeneca announced it would buy the US-based gene therapy developer at a rare 660% premium for $68 million. LogicBio is developing gene-editing therapies to treat pediatric rare diseases, such as methylmalonic acidemia, in which the body cannot break down certain proteins and fats. (10/3)

FiercePharma: Constipation Prescribing Awareness Remains Low Despite Known Risks of Long-Term OTC Drugs: Report

Although patients widely acknowledge their recurrent or chronic constipation, their knowledge of prescription and therapy options is poor, according to a new report by Phreesia. (Renfroh, 4.10.)

ScienceDaily: Robotic Drug Capsule can deliver drugs to the gut

A new drug capsule can help large proteins like insulin and small molecule drugs get absorbed in the digestive tract. The capsule has a robotic cap that rotates and tunnels through the mucus barrier when it reaches the small intestine, allowing drugs carried by the capsule to enter the cells lining the intestine. (Massachusetts Institute of Technology, 9/29)

In Legal News —

Reuters: Eli Lilly loses bid to cancel patents on migraine drug Teva ahead of Emgality trial

A federal judge in Boston on Monday denied Eli Lilly & Co’s request to invalidate three patents held by Teva Pharmaceuticals International GmbH in a long-running legal battle over the companies’ competing migraine drugs. (UK, 10/4)

Reuters: US Supreme Court upholds Novartis motion to stop generic Gilenya rivals

The U.S. Supreme Court on Thursday agreed to stop an appellate court mandate that Novartis Pharmaceuticals Corp. said it would greenlight up to 20 generic versions of its blockbuster multiple sclerosis drug, Gilenya. (UK, 29.9.)

FiercePharma: In the Daiichi case, the court upholds the 177.8 million jury decision against Novartis

In a long-running patent case against pharmaceutical giant Novartis, Daiichi Sankyo has won a decisive victory in the US District Court for the Northern District of California. (Becker, 4.10.)

This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.

Leave a Comment